不同化疗方案一线治疗老年晚期胃癌近期疗效分析

目的探讨mFOLFOX、SOX、XELOX 3种化疗方案一线治疗老年晚期胃癌的近期疗效及不良反应。方法回顾分析了62例晚期老年胃癌病例,根据接受方案不同分为3组,比较各组之间的近期疗效与不良反应。结果 mFOLFOX组,SOX组,XELOX组近期有效率(RR)分别为:41.4%、46.7%、38.9%;疾病控制率(DCR)分别为:79.3%、80%、77.8%。各组之间疗效均无统计学差异。3组不良反应主要为:胃肠道反应、血液学毒性、外周神经毒性、乏力虚弱、口腔黏膜炎。在口腔黏膜炎、乏力虚弱及手足综合征的发生率上具有统计学差异,其中口腔黏膜炎以XELOX组最高(44.4%)、乏力虚弱以mFOLFOX组最高(55.2%),手足综合征在XELOX组中发生率最高(38.9%)。结论 mFOLFOX、SOX、XELOX这3类以氟尿嘧啶及其衍生物和奥沙利铂的两药联合方案在晚期老年胃癌患者一线治疗中疗效确切且相当,不良反应可耐受。

Clinincal Analysis of Different Chemotherapy Regimens as Fist-line treatment for Advanced Gastric Cancer in Gerontal Patients

Objective To analyze the clinical efficacy and the side effects of different regimens in gerontal patients of advanced gastric cancer.Methods 62 gerontal patients with advanced gastric cancer were treated by different chemotherapy regimens: mFOLFOX,SOX and XELOX.The efficacy and the adverse reaction of the there regiments were evaluated.Results In the regimen of mFOLFOX,SOX and XELOX,the response rate were 41.4%,46.7%,38.9% respectively;the disease control rate were 79.3%,80%,77.8% respectively.There were n...